TOX: a potential new immune checkpoint in cancers by pancancer analysis

• Published in: Discover. Oncology 2024-08, Vol.15 (1), p.354-17
• Main Authors: Qiu, Shengliang, Lin, Weiye, Zhou, Zhengyang, Hong, Qianran, Chen, Shuangyu, Li, Jiayang, Zhong, Fengyun, Zhou, Qinfeng, Cui, Dawei
• Format: Article
• Language: English
• Subjects: Antibodies; Cancer; Cancer prognosis; Cancer Research; Cells; Gene expression; Genomes; Immune checkpoint; Immunotherapy; Internal Medicine; Localization; Lymphocytes; Medical prognosis; Medicine; Medicine & Public Health; Molecular Medicine; Multiomics technologies; Mutation; Oncology; Proteins; Radiotherapy; Surgical Oncology; Survival analysis; TOX; Tumorigenesis; Tumors
• ISSN: 2730-6011; 2730-6011
• DOI: 10.1007/s12672-024-01236-1

Background Thymocyte selection-associated HMG-BOX (TOX) belongs to a family of transcription factors containing a highly conserved region of the high mobility group box (HMG-Box). A growing body of research has shown that TOX is involved in the occurrence and development of tumors and promotes T-cell exhaustion. We assessed the role of TOX with The Cancer Genome Atlas (TCGA) Pancancer Data. Methods TOX expression was examined with RNA-seq data from the TCGA and Genotype-Tissue Expression (GTEx) databases. The genetic alteration status and protein level of TOX were analyzed using databases, including the Human Protein Atlas (HPA), GeneCards, and STRING. The prognostic significance was estimated with survival data from the TCGA. Moreover, R software was used for enrichment analysis of TOX. The relationship between TOX and immune cell infiltration was assessed with the Tumor Immune Estimation Resource (TIMER) 2.0 database and the “CIBERSORT” method. The correlation between TOX and immune checkpoints was further explored. Immunohistochemical analysis was used to further verify the difference in TOX expression between cancerous and paracancerous tissues, and cell viability was evaluated using a CCK-8 assay. Results In most cancer types in the TCGA cohort, differential TOX expression was observed. The genetic alteration status and protein level of TOX were examined, and the prognosis of cancers was associated with TOX expression. Moreover, TOX levels were closely related to different immune-related pathways, immune cell infiltration and immune checkpoints. Additionally, significant differences in TOX expression between several cancerous and paracancerous tissues were validated. Furthermore, TOX clearly impacted the viability of cancer cells. Conclusions TOX, a potential biomarker for cancer, may be involved in the regulation of the immune microenvironment and can be used for new targeted drugs.